Navigation Links
Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
Date:1/7/2008

mong existing oral OAB treatments, according to Dr. Sand. "Watson's oxybutynin gel is an elegant topical formulation that is clear, odorless and fast drying and will offer healthcare providers a unique treatment option for OAB patients," said Dr. Sand.

The Phase 3 multi-center, double blind, placebo-controlled study evaluated the efficacy and safety of OTG in 789 patients with overactive bladder. The primary objective of the study was to demonstrate that daily treatment of a 1g dose (approximately 1 mL) of OTG for 12 weeks was superior to placebo for the relief of OAB symptoms. Changes from baseline to endpoint were calculated from a three-day patient urinary diary and included a reduction in incontinence episodes and urinary frequency, and an increase in void volume. Additionally, 216 patients participated in a 14-week, open label, safety-extension study for a total of 26 weeks. During the double-blind portion of the trial, highly statistically significant improvements relative to placebo were seen on all of these endpoints.

Secondary endpoints also included a patient assessment of incontinence-specific, quality-of-life measures using multiple validated instruments including the Incontinence Impact Questionnaire (IIQ) and the King's Health Questionnaire, which indicated a significant positive effect of OTG treatment on quality-of-life total and subscale scores at endpoint in comparison with placebo.

OTG was well tolerated in the study. No serious adverse events related to the treatment were reported. Dry mouth (6.9%) and application site pruritis (2.1%) were the only treatment-related side effects reported at levels greater than 2%. Treatment-related adverse events that resulted in study discontinuation during the double-blind period were low (1.8%) and the similar for both the treatment and placebo groups.

Phase 1 studies have demonstrated that the steady-state plasma levels of oxybutynin show little fluctuation during the 24-hour dosin
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
5. Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF
6. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
9. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
10. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
11. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... 15, 2014 Tegra Medical is very pleased to announce ... its new Chief Executive Officer.  Mark was promoted from his ... overseen the company,s four facilities in Massachusetts ... King joined Tegra Medical in 2012 with 20+ years of ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... , CAMBRIDGE, Mass., Oct. 14 Northern Light ( ... EBSCO Publishing (EBSCO) ( www.ebscohost.com ) that ... than 4,000 bio-pharmaceutical, health sciences and general business magazines, ... strategic research portals. SinglePoint users who also subscribe ...
... Luminous Medical, Inc. announced today that it has ... for exclusive rights to incorporate its glucose sensor into ... its monitor to enable clinicians to control hyperglycemia in ... was planning to use a sensing technology based on ...
Cached Medicine Technology:Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing 2Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing 3Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor 2
(Date:4/24/2014)... Philadelphia, Pa. (April 24, 2014) - Contact lenses coated with ... contact lens-related infections, reports a study in Optometry ... American Academy of Optometry . The journal is published ... Wolters Kluwer Health . , Studies in animals and ... with the antimicrobial peptide melimine, according to the new research ...
(Date:4/24/2014)... be boring and irrelevant, could offer an alternative to ... Dr Milena Furtado, and her team from the Australian ... heart cell fibroblast is a close relative to a ... , In research published today in Circulation Research ... unique cells due to their genetic program, and will ...
(Date:4/24/2014)... in the world to discover a gene mutation in ... Ameloblastoma is an odontogenic tumour with a high tendency ... in the posterior of the lower jaw. Ameoloblastomas are ... the jaws as well as loss of several teeth. ... surgery and the recurrence of ameloblastoma, but finding such ...
(Date:4/24/2014)... by a scientist at the University of York reveals ... the development of the nervous system may also play ... A research team, led by Dr Will Brackenbury, ... Biology at York, has studied how voltage-gated sodium channels ... are found in the membranes of excitable cells, such ...
(Date:4/23/2014)... Spokane have developed a new way to detect ... the wheel. , Their recently patented technology is ... in drowsy driversand offers an affordable and more ... detection systems. , Van Dongen"Video-based systems that use ... out of its lane are cumbersome and expensive," ...
Breaking Medicine News(10 mins):Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Boring cells could hold the key to heart disease 2Health News:Breast cancer replicates brain development process 2Health News:WSU innovation improves drowsy driver detection 2
... Goodwin HealthDay Reporter , WEDNESDAY, Feb. 9 ... cancer cell genome revealed never-before-seen changes in DNA that ... By mapping the full genetic blueprint of the tumor, ... development of more targeted drugs and a better understanding ...
... Salamon HealthDay Reporter , WEDNESDAY, Feb. 9 ... than doubled the progression-free survival time for patients with ... new studies. In separate phase 3 trials by ... extended the survival of participants with advanced pancreatic neuroendocrine ...
... parks and recreation sites may be healthier, more physically ... to Penn State researchers. Investments in parks and recreational ... say Geof Godbey, professor emeritus of leisure studies, and ... "There is a strong relationship between how much money ...
... Feb. 9 (HealthDay News) -- About one in 10 ... after. Though typically harmless, some may need treatment because ... "There are several different types of birthmarks, so it ... considering any possible treatments," dermatologist Dr. Sheila Fallon Friedlander, ...
... diagnose heart disease, cancers, HIV and other diseases quickly ... The microsponges are an essential component of Rice University,s ... paper in the journal Small . ... Bioengineering and Chemistry, and his colleagues at Rice,s BioScience ...
... plan from an arm of the National Institutes of ... of most single-gene disorders and gaining new insights into ... to more accurate diagnoses, new drug targets and the ... therapeutic options, according to the plan from the National ...
Cached Medicine News:Health News:First Look at Prostate Cancer Genome Yields Insights 2Health News:First Look at Prostate Cancer Genome Yields Insights 3Health News:2 Experimental Drugs Show Promise for Rare Pancreatic Cancer 2Health News:2 Experimental Drugs Show Promise for Rare Pancreatic Cancer 3Health News:Key to better health care may be a walk in the park 2Health News:Not All Birthmarks Harmless, Expert Says 2Health News:Microsponges from seaweed may save lives 2Health News:Microsponges from seaweed may save lives 3Health News:NHGRI charts course for the next phase of genomics research 2Health News:NHGRI charts course for the next phase of genomics research 3Health News:NHGRI charts course for the next phase of genomics research 4
... Carpal Solution offers relief from CTS pain ... different from other over-the-counter CTS treatments. It ... during sleep, the Carpal Solution gently reshapes ... Tunnel and eliminates hand pain, numbness and ...
... of Hemoglobin S in patient samples. Each ... and 20l of anticoagulated whole blood or ... test kit contains two bottles of phosphate ... and two vials of Sodium Hydrosulfite reagent ...
... tube for the collection, transport and retention ... flow cytometry. The preservative contained in Cyto-Chex ... blood cell cluster of differentiation (CD) markers ... collected in Cyto-Chex BCT are stable at ...
Streck-ONYX-Pack is specially designed for use on Coulter® ONYX Series instruments. Each pack contains diluent and lysing agent. The shelf life is one year from date of manufacture....
Medicine Products: